title: The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
abstract: OBJECTIVE
  This study aimed to evaluate the subjective well-being and attitudes toward antipsychotic medication of patients with schizophrenia who had switched to paliperidone extended release (ER).
  
  
  METHODS
  A total of 291 patients with schizophrenia treated with antipsychotics participated in this open-label, 24-week switching study. The primary outcome measures were the Subjective Well-Being under Neuroleptic Treatment Scale-short version (SWN-K) and the Drug Attitude Inventory (DAI). The Krawiecka scale, Clinical Global Impression-Schizophrenia (CGI-SCH), Personal and Social Performance scale (PSP) were used to evaluate psychopathology and psychosocial functioning, respectively.
  
  
  RESULTS
  Data from a total of 243 subjects who received the study medication and had at least one follow-up assessment without a major protocol violation were analyzed. Scores on the DAI and SWN-K showed significant improvement between baseline and end-point measurements beginning during the second week. Scores on the Krawiecka scale, all five subscales of the CGI-SCH scale, and the PSP scale were also significantly improved at the end point compared with the baseline. Significant predictors of improvements in the SWN-K and DAI after a switch to paliperidone ER were baseline scores, reductions in scores on the Krawiecka scale, and previous risperidone use. A clinically relevant increase in body weight (≥7% weight gain) occurred in one-fourth of the participants who completed the 24-week study.
  
  
  CONCLUSIONS
  Switching to paliperidone ER improved the subjective well-being and attitudes towards antipsychotic medication in patients with schizophrenia. Exploratory analyses revealed that these improvements were particularly pronounced in patients who had been treated with risperidone before treatment with paliperidone ER.
authors.affiliation: Department of Psychiatry, Chonnam National University Medical School, Gwangju 501-746, Republic of Korea.
authors.forename: Sung-Wan
authors.initials: SW
authors.lastname: Kim
authors.forename: Jin-Sang
authors.initials: JS
authors.lastname: Yoon
authors.forename: Yong Sik
authors.initials: YS
authors.lastname: Kim
authors.forename: Yong-Min
authors.initials: YM
authors.lastname: Ahn
authors.forename: Chul-Eung
authors.initials: CE
authors.lastname: Kim
authors.forename: Hyo-Jin
authors.initials: HJ
authors.lastname: Go
authors.forename: Ik-Seung
authors.initials: IS
authors.lastname: Chee
authors.forename: Sung-Won
authors.initials: SW
authors.lastname: Jung
authors.forename: Young-Chul
authors.initials: YC
authors.lastname: Chung
authors.forename: Young-Don
authors.initials: YD
authors.lastname: Kim
authors.forename: Soohyun
authors.initials: S
authors.lastname: Joe
authors.forename: Jonghun
authors.initials: J
authors.lastname: Lee
authors.forename: Young-Joon
authors.initials: YJ
authors.lastname: Kwon
authors.forename: Bo-Hyun
authors.initials: BH
authors.lastname: Yoon
authors.forename: Young-Myo
authors.initials: YM
authors.lastname: Jae
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000068882:Paliperidone Palmitate; D010549:Personal Satisfaction; D011569:Psychiatric Status Rating Scales; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D007555:Isoxazoles; D011743:Pyrimidines; D000068882:Paliperidone Palmitate